Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TRANSITION THERAPEUTICS INC. T.TTH

"Transition Therapeutics Inc is a product-focused biopharmaceutical company. The Company is engaged in developing therapeutics for disease indications with markets. Its technologies are focused on the treatment of Alzheimer's disease and diabetes."


TSX:TTH - Post by User

Post by deninsaskon Dec 24, 2007 12:23pm
245 Views
Post# 14120294

Re: NEWS..GMP Bang on estimate. Target $32.50

Re: NEWS..GMP Bang on estimate. Target $32.50 2bmb its the analysts that estimate the milestone payments. Elan & Transition don't make public the details of their $200,000,000.00 Co-Development Deal. Look at it this way.....Transition has received $12.5 Million from Elan in the last 7 1/2 weeks. I think it was RBC had estimated the $10mil figure. Looks like GMP got this one right. Bang on the nose. They have a $32.50 Target set for Transition. From the Report....."In our view, Transition could sign a higher value partnership in diabetes. In our opinion, Transition will be better suited to partner its diabetes programs with other firms that are focusing their efforts on this segment of the market. As such, we are confident that Transition will be able to sign a new partnership agreement in the near future and expect that their previously announced positive Phase II data will be able to entice numerous companies in the space. We believe that ideal partners for Transition could be Amylin and Eli Lily as both firms are currently investigating complementary programs in diabetes and are leaders in this particular segment of the market." ......."Besides Transition’s diabetes programs, we are also encouraged by the Company’s clinical development of its Alzheimer’s candidate, AZD-103. AZD-103 has exhibited positive results thus far with pharmacokinetic and plasma studies demonstrating that AZD-103 was safe and well tolerated at all doses and dosing regimens with no severe or serious adverse events being reported. Hence, with positive results in hand, we expect Phase II testing to stay on track and begin by calendar year-end or early 2008 via partner Elan Pharmaceuticals"..........GMP Bang on AGAIN. Note that Dosing has already begun for the Trial of which they speak. Merry Christmas ALL
Bullboard Posts